8-K current report · filed Aug 4, 2026

LEMAITRE VASCULAR INC (LMAT) 8-K Current Report: August 4, 2026

Item EX-99.1Item 2.02LMAT overview

Short answer

LEMAITRE VASCULAR INC (LMAT) filed an 8-K current report with the SEC on August 4, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Preliminary financial and operational results for quarter ended June 30, 2026 announced August 4, 2026.

LEMAITRE VASCULAR INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Preliminary financial and operational results for quarter ended June 30, 2026 announced August 4, 2026
  • Investors should review Exhibit 99.1 for revenue, profitability and operating metrics
  • Preliminary status means reported figures remain subject to change before final results

Item EX-99.1 · Exhibit EX-99.1

  • Q2 sales $70.4mm, up 10% organically, with organic growth reaching 12% excluding catheters
  • Gross margin expanded 210 bps to 72.1%; operating income rose 26% to $20.4mm
  • Artegraft sales increased 34%; product approved in 56 countries and represented 21% of sales
  • Full-year guidance midpoint: sales $276.3mm, operating income $76.8mm, EPS $2.89
  • $376.2mm cash supports international warehouse expansion, while $0.25/share dividend and $100.0mm repurchase authorization enhance shareholder returns

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other LEMAITRE VASCULAR INC 8-K filings

Get the next LMAT 8-K as it lands

Follow LMAT for push alerts, or ask the research agent what this filing means.